Greater effort should be directed at detecting and aggressively treating prostate cancer metastasis earlier, an approach made possible with the advent of highly sensitive and specific molecular imaging techniques and potent anticancer agents.
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
Investigators reported findings from the first randomized trial to evaluate the use of metastasis-directed therapy with hormone therapy in patients with oligometastatic prostate cancer.
Investigators characterized the toxicity of stereotactic body radiotherapy for oligometastases from predominantly prostate, colorectal, breast, and lung cancer.
New findings suggest active surveillance should be performed in this population and should not preclude transplant eligibility, according to investigators.
Pooled analysis of 12 randomized trials suggests use of concurrent/adjuvant androgen deprivation therapy in combination with prostate-only radiotherapy may improve outcomes
Researchers sought to determine the relationship between body composition and pelvic fat distribution and prostate cancer aggressiveness and recurrence.
Each 10% increase in PSA screening rates was significantly associated with a 9% decrease in the metastatic prostate cancer rates, according to a study of VA medical centers.
